neoplasms

Summary

Alias: benign neoplasms
Summary: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Webpages

  1. neurosurgery articles (diagnosis, treatment, surgical treatment, prognosis, follow-up) - emedicine
    emedicine.medscape.com/neurosurgery
  2. cas classes
    www.med.univ-rennes1.fr/cerf/iconocerf/R/
  3. hydrops fetalis
    www.peds.umn.edu/divisions/neonatology/hydrops.html
  4. pathology
    www.med-ed.virginia.edu/courses/path/gyn/ovary3.cfm
  5. disseminated intravascular coagulation
    www.addl.purdue.edu/newsletters/2005/Winter/DIC.htm
  6. department of laboratory medicine & pathology - dmed 514: interstitial nephritis
    www.lmp.ualberta.ca/education/dmed514/interstitialnephritis/ ...
  7. medical subject headings for oral surgery: tufts university hirsh health sciences library
    www.library.tufts.edu/hsl/education/oralmesh.html
  8. nerve: autoantibodies
    neuromuscular.wustl.edu/nother/autoantibody.html
  9. publications of benedikt brors
    www.dkfz.de/tbi/publications/Author/BRORS-B.html
  10. nu570: digital library: lectures: the endocrine system
    jeffline.tju.edu/Education/dl/NU570/library/lectures/11a.htm ...

Research Grants

  1. Studies of Environmental and Occupational Exposures
    Jay Lubin; Fiscal Year: 2002
  2. North Carolina A&T University-Wake Forest Cancer Center partnership (1of 2)
    Steven A Akman; Fiscal Year: 2008
  3. Role of KSHV in AIDS Malignancies
    Gary S Hayward; Fiscal Year: 2006
  4. Molecular Basis Of Pathogenesis Of Murine Leukemia Virus
    S K Chattopadhyay; Fiscal Year: 2005
  5. Genetic Susceptibility to Loss of Tumor Suppressor Gene
    JOHN EDGAR FRENCH; Fiscal Year: 2006
  6. Descriptive Studies and Record Linkage
    Susan S Devesa; Fiscal Year: 2006
  7. Vanderbilt In Vivo Cellular and Molecular Imaging Center
    JOHN C johngore@vanderbiltedu CHANCELLOR'S UNIVERSITY PROFESSOR GORE; Fiscal Year: 2009
  8. Vanderbilt In Vivo Cellular and Molecular Imaging Center
    John C Gore; Fiscal Year: 2008
  9. Glial Dysfunction in Ataxia Telangiectasia
    Margot Mayer-Proschel; Fiscal Year: 2008
  10. c-IMycI-induced B cell and plasma cell neoplasms in mice
    SIEGFRIED D JANZ; Fiscal Year: 2005

Publications

  1. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives
    Bharat B Aggarwal
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cell Cycle 4:1201-15
  2. Cannabinoid receptor systems: therapeutic targets for tumour intervention
    Sarah Jones
    Molecular Pharmacology Group, Biomedical Sciences Division, School of Applied Sciences, University of Wolverhampton, Wulfruna Street, WV1 1SB, UK
    Expert Opin Ther Targets 7:749-58
  3. Therapeutic potential of target of rapamycin inhibitors
    John B Easton
    St Jude Childrens Research Hospital, Department of Molecular Pharmacology, 332 N Lauderdale Street, Memphis, TN 38105 2794, USA
    Expert Opin Ther Targets 8:551-64
  4. Proteasome inhibition: a new approach for the treatment of malignancies
    Jean Philippe Spano
    Département d oncologie médicale, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France
    Bull Cancer 92:E61-6, 945-52
  5. Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47
  6. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo
    Fang Tian
    Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Science, Chinese Academy of Sciences, PR China
    Cancer Biol Ther 4:874-82
  7. Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative
    Eui-Yeun Yi
    Department of Molecular Biology, Pusan National University, Pusan 609-735, Korea
    Int J Oncol 25:365-72
  8. Modulation of tumor induced angiogenesis in Ehrlich ascites tumor
    S Ghosh
    Dept of Metabolic Regulation, Chittaranjan National Cancer Institute, Kolkata, India
    J Exp Clin Cancer Res 23:681-90
  9. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics
    Lyubomir T Vassilev
    Roche Research Center, Hoffman La Roche Inc, Nutley, New Jersey 07110, USA
    Cell Cycle 3:419-21
  10. Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis
    Lynn Bonham
    Cell Therapeutics, Inc, 201 Elliott Avenue West, Suite 400, Seattle, WA 98119, USA
    Expert Opin Ther Targets 7:643-61

Scientific Experts

Detail Information

Webpages122 found, 30 most recent shown here

  1. neurosurgery articles (diagnosis, treatment, surgical treatment, prognosis, follow-up) - emedicine
    emedicine.medscape.com/neurosurgery
  2. cas classes
    www.med.univ-rennes1.fr/cerf/iconocerf/R/
  3. hydrops fetalis
    www.peds.umn.edu/divisions/neonatology/hydrops.html
  4. pathology
    www.med-ed.virginia.edu/courses/path/gyn/ovary3.cfm
  5. disseminated intravascular coagulation
    www.addl.purdue.edu/newsletters/2005/Winter/DIC.htm
  6. department of laboratory medicine & pathology - dmed 514: interstitial nephritis
    www.lmp.ualberta.ca/education/dmed514/interstitialnephritis/ ...
  7. medical subject headings for oral surgery: tufts university hirsh health sciences library
    www.library.tufts.edu/hsl/education/oralmesh.html
  8. nerve: autoantibodies
    neuromuscular.wustl.edu/nother/autoantibody.html
  9. publications of benedikt brors
    www.dkfz.de/tbi/publications/Author/BRORS-B.html
  10. nu570: digital library: lectures: the endocrine system
    jeffline.tju.edu/Education/dl/NU570/library/lectures/11a.htm ...
  11. pa570: learning resouces: lectures: the endocrine system
    jeffline.tju.edu/Education/dl/PA570/lr/lectures/11a.html
  12. bone tumors
    pedclerk.bsd.uchicago.edu/bonetumors.html
  13. pulmonary pathology index
    library.med.utah.edu/WebPath/LUNGHTML/LUNGIDX.html
  14. head and neck
    www.path.uiowa.edu/cgi-bin-pub/vs/fpx_browse.cgi?cat=o_hn&am ...
  15. the university of adelaide library | environmental health
    www.library.adelaide.edu.au/guide/med/pubhealth/environ.html
  16. dora
    www.radil.missouri.edu/info/dora/mousepag/resp.html
  17. carbohydrate binding proteins database
    web.mit.edu/glycomics/moleculepages/cbp/galectins/gal3_human ...
  18. chapter 20: mass lesions
    www.dartmouth.edu/~dons/part_2/chapter_20.html
  19. pd dr. med. rüdiger proßt - publikationen
    www.prosst.de/pageID_7123493.html
  20. information resources on ferrets
    www.nal.usda.gov/awic/pubs/ferrets/neoplasia.htm
  21. eletters — the royal college of surgeons of england
    www.rcseng.ac.uk/publications/eletters
  22. welcome to tulane pathology & laboratory medicine
    www1.omi.tulane.edu/departments/pathology/faculty/haque/haqu ...
  23. tumors of dog testis
    www.vet.uga.edu/VPP/clerk_anat/sabatino/index.php
  24. thymoma
    www.derma.de/bochum_old/Klinikschwerpunkte/Histologie/vortra ...
  25. testosterone, lc/ms/ms from quest diagnostics
    www.questdiagnostics.com/hcp/topics/endo/testosterone.html
  26. johns hopkins medicine stereotactic radiosurgery
    www.radonc.jhmi.edu/radiosurgery/disorders/glioma.html
  27. cytologic diagnosis of transitional cell carcinoma in dogs and cats
    www.vet.uga.edu/VPP/clerk/frost/index.php
  28. the new who classification of brain tumors
    www1.wfubmc.edu/surg-sci/ns/newwhobt.html

Research Grants62

  1. Studies of Environmental and Occupational Exposures
    Jay Lubin; Fiscal Year: 2002
    ..Investigators have examined the pattern of multiple occurrences of four radiation-related neoplasms in a radiation-exposed cohort of 2795 patients receiving conventional radiation treatments for benign conditions ..
  2. North Carolina A&T University-Wake Forest Cancer Center partnership (1of 2)
    Steven A Akman; Fiscal Year: 2008
    ..glioblastoma (Grade IV). Glioblastomas differ from lower grades of astrocytic neoplasms; by being extremely aggressive, highly neovascularized and proliferative, as well as migratory/infiltrative...
  3. Role of KSHV in AIDS Malignancies
    Gary S Hayward; Fiscal Year: 2006
    ..an important target for the investigation of the pathogenesis and ultimately the specific treatment of these neoplasms. The overall goal of this Program Project is to investigate how KSHV takes control of vascular endothelial cells ..
  4. Molecular Basis Of Pathogenesis Of Murine Leukemia Virus
    S K Chattopadhyay; Fiscal Year: 2005
    ..the last 50 years or so researchers have used both inbred and outbred mice to study both spontaneous and induced neoplasms. Murine leukemia viruses (MuLVs) have been implicated in the spontaneous development of hematopoietic neoplasms ..
  5. Genetic Susceptibility to Loss of Tumor Suppressor Gene
    JOHN EDGAR FRENCH; Fiscal Year: 2006
    ..B6C3F1-Trp53tm1Brd N12 (12th backcross generation) haploinsufficient mice develop hematopoietic stem cell (HSC) neoplasms after exposure to human carcinogens (including ionizing radiation, benzene, cyclophosphamide, melphalan, etc...
  6. Descriptive Studies and Record Linkage
    Susan S Devesa; Fiscal Year: 2006
    ..A comprehensive analysis of 114,548 lymphoid neoplasms diagnosed during 1992-2001 classified according to the 2001 World Health Organization (WHO) lymphoma ..
  7. Vanderbilt In Vivo Cellular and Molecular Imaging Center
    JOHN C johngore@vanderbiltedu CHANCELLOR'S UNIVERSITY PROFESSOR GORE; Fiscal Year: 2009
    ..to improve the treatment of human metastatic CRC and may serve as a paradigm for the treatment of other solid neoplasms. To carry out this task, we propose a combination of pre-clinical studies in a conventional xenograft mouse ..
  8. Vanderbilt In Vivo Cellular and Molecular Imaging Center
    John C Gore; Fiscal Year: 2008
    ..to improve the treatment of human metastatic CRC and may serve as a paradigm for the treatment of other solid neoplasms. To carry out this task, we propose a combination of pre-clinical studies in a conventional xenograft mouse ..
  9. Glial Dysfunction in Ataxia Telangiectasia
    Margot Mayer-Proschel; Fiscal Year: 2008
    ..neuropathy, infertility, translocations of chromosomes 7 and 14, underdeveloped thymus, and increased risk of neoplasms leading to poor quality of life...
  10. c-IMycI-induced B cell and plasma cell neoplasms in mice
    SIEGFRIED D JANZ; Fiscal Year: 2005
    We have continued our studies on the pathogenesis of mouse B cell and plasma cell neoplasms that are induced by chromosomal T(12;15) translocations that result in the deregulated expression of the proto-oncogene Myc (c-myc)...
  11. Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom
    VICENTE notariov@georgetownedu PROFESSOR NOTARIO; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Tumors of the Ewing's sarcoma family (ESFT) are solid, highly malignant neoplasms of the bone and soft tissues that most often affect children and adolescents, being the second most common bone ..
  12. Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom
    Vicente Notario; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Tumors of the Ewing's sarcoma family (ESFT) are solid, highly malignant neoplasms of the bone and soft tissues that most often affect children and adolescents, being the second most common bone ..
  13. Protein kinase A and Human Cancer: Translational Researc
    YOON CHO CHUNG; Fiscal Year: 2006
    ..pigmented nodular adrenocortical disease (PPNAD), pituitary adenoma, thyroid adenoma or carcinoma, testicular neoplasms, and ovarian tumors...
  14. MRR1/Ahi-1: A Novel Candidate Tumor Supressor Gene
    Eric Westin; Fiscal Year: 2004
    ..described Ahi-1 (Abelson helper integration) gene altered by viral insertion in a variety of murine T and B cell neoplasms. Based on a prototype human cDNA clone, the human MRR1/Ahi-1 gene encodes a novel nuclear WD-protein with an ..
  15. Omega-6 Fat Promotion of Mutant Kras-Induced Pancreatic Neoplasia
    Paul Grippo; Fiscal Year: 2008
    ..behind the role of w-6 fat in the development and progression of mutant Kras-induced pancreatic intraepithelial neoplasms (PanINs) will illuminate dietary effects on pancreatic cancer development in the human population...
  16. Effect of chronic low-dose phthalate exposure on the immature primate testis
    Ina Dobrinski; Fiscal Year: 2008
    ..to human health and has been implicated in both the apparent decline of male fertility and a rise in testicular neoplasms. Phthalate esters are widely used as plasticizers in consumer products and can leach into the environment, ..
  17. Folate, 1-Carbon Nutrients, Gene Variants & Colon Cancer
    David J Hunter; Fiscal Year: 2007
    ..studies that have examined the relationship between dietary folate intake and the risk of developing colorectal neoplasms, have reported that higher folate intakes are associated with lower risk...
  18. Characterization of Primate Retroviruses
    RAOUL BENVENISTE; Fiscal Year: 2002
    ..is manifested by progressive weight loss, persistent diarrhea, anemia, opportunistic infections, and unusual neoplasms. Since the experimental infection of macaques with SIV results in similar clinical outcomes, animals used in ..
  19. Omega-6 Fat Promotion of Mutant Kras-Induced Pancreatic Neoplasia
    Paul Grippo; Fiscal Year: 2007
    ..behind the role of w-6 fat in the development and progression of mutant Kras-induced pancreatic intraepithelial neoplasms (PanINs) will illuminate dietary effects on pancreatic cancer development in the human population...
  20. Isolation & Evaluation of Anticarcinogenic Glucosinolate
    Paul Talalay; Fiscal Year: 2005
    ..elevation of glutathione levels are now recognized as effective strategies for reducing the risk of developing neoplasms caused by electrophilic carcinogens and reactive forms of oxygen...
  21. An Intra-Neoplasm Genetic Diversity Assay
    Carlo C Maley; Fiscal Year: 2008
    ..applicant): Effective cancer prevention depends on distinguishing between indolent and progressive pre-malignant neoplasms, so that the cost and risks of interventions can be focused on patients likely to progress to cancer, while ..
  22. Functional analysis of the CYLD tumor suppressor
    Julide T Celebi; Fiscal Year: 2008
    ..have been demonstrated in families with FC, and loss of heterozygosity at the CYLD locus has been found in these neoplasms, suggesting that CYLD functions as a tumor suppressor...
  23. Functional analysis of the CYLD tumor suppressor
    Julide T Celebi; Fiscal Year: 2007
    ..have been demonstrated in families with FC, and loss of heterozygosity at the CYLD locus has been found in these neoplasms, suggesting that CYLD functions as a tumor suppressor...
  24. Mouse Model of Pancreatic Tumorigenesis with Dysregulation of mTOR
    CHONGJUAN cwei@mdandersonorg WEI; Fiscal Year: 2009
    ..As the mice age, they develop cystic malformations that resemble the intrapapillary mucinous neoplasms (IPMNs) seen in humans with PJS as well as sporadic cases...
  25. Mouse Model of Pancreatic Tumorigenesis with Dysregulation of mTOR
    Marsha L Frazier; Fiscal Year: 2008
    ..As the mice age, they develop cystic malformations that resemble the intrapapillary mucinous neoplasms (IPMNs) seen in humans with PJS as well as sporadic cases...
  26. ENDOGENOUS MODULATION OF COCHLEA INJURY
    Leonard P Rybak; Fiscal Year: 2006
    ..Cisplatin is a potent chemotherapeutic agent widely used to treat patients with a variety of malignant neoplasms. Severe side effects including nephrotoxicity, neurotoxicity and ototoxicity limit doses that can be used...
  27. Control of Skeletal Growth by ATF-2
    PHYLLIS A LUVALLE; Fiscal Year: 2008
    ..chondrodysplasias, overgrowth diseases like Beckwith Wiedernann syndrome, osteochondromas and other cartilage neoplasms, and some forms of osteoarthritis...
  28. Control of Skeletal Growth by ATF-2
    PHYLLIS A LUVALLE; Fiscal Year: 2007
    ..chondrodysplasias, overgrowth diseases like Beckwith Wiedernann syndrome, osteochondromas and other cartilage neoplasms, and some forms of osteoarthritis...
  29. Influence of acid reflux on stromal epithelial interaction in Barrett?s esophagus
    GANAPATHY A prasadganapathy@mayoedu PRASAD; Fiscal Year: 2009
    ..Myofibroblast derived growth factors are known to promote proliferation of epithelial neoplasms 5-7...
  30. Influence of acid reflux on stromal epithelial interaction in Barrett?s esophagus
    Ganapathy A Prasad; Fiscal Year: 2008
    ..Myofibroblast derived growth factors are known to promote proliferation of epithelial neoplasms 5-7...
  31. Modeling Neoplastic Progression in Barrett's Esophagus
    CARLO C (Contact) cmaley@wistarorg PEPPER MALEY; Fiscal Year: 2009
    ..b>Neoplasms progress to malignancy through a process of clonal evolution...
  32. PHYSICIANS HEALTH STUDY--CONTINUED FOLLOW UP
    Julie E Buring; Fiscal Year: 2002
    ..with beta carotene or placebo, there were no differences between the groups in the rates of malignant neoplasms, cancer mortality, cardiovascular mortality, or mortality from all causes...
  33. HISTOMETRIC ANALYSIS OF PREMALIGNANT ENDOMETRIAL LESIONS
    FRANCISCO AR GARCIA; Fiscal Year: 2003
    ..It accounts for about 36,000 cases of invasive cancer each year and is among the top five neoplasms affecting women...
  34. SSDP2 Gene Pathway in Myeloid Neoplasms
    Lalitha Nagarajan; Fiscal Year: 2006
    ..Thus, the incidence of secondary myeloid neoplasms is likely to increase as we cure other forms of cancer and 50% of secondary myeloid malignancies harbor ..
  35. Molecular Classification of Suspicious Thyroid Tumors
    Martha A Zeiger; Fiscal Year: 2008
    ..Research Premise Although others and we have documented various genetic alterations in thyroid neoplasms, no specific alteration(s) can reliably distinguish benign from malignant lesions...
  36. Molecular Classification of Suspicious Thyroid Tumors
    Martha A Zeiger; Fiscal Year: 2006
    ..Research Premise Although others and we have documented various genetic alterations in thyroid neoplasms, no specific alteration(s) can reliably distinguish benign from malignant lesions...
  37. CYP1A1, estrogen metabolism and ovarian carcinogenesis
    Shuk-Mei Ho; Fiscal Year: 2004
    ..Although overexpression of CYP1s has been linked to the development of several neoplasms an analogous knowledge base for OC is presently unavailable...
  38. Endogenous Modulation of Cochlear Injury
    Leonard P Rybak; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Cisplatin is a potent chemotherapeutic agent widely used to treat malignant neoplasms. Side effects, like ototoxicity compromise the quality of life of cancer survivors...
  39. Genetic and Pharmacogenetic Modifiers of Cancer Risk and
    Mark H Greene; Fiscal Year: 2006
    ..a) analysis of the non-invasive breast cancers which developed in P1 subjects; (b) analysis of the endometrial neoplasms from this same study; and (c) genotyping of a random sample of the entire P1 cohort, to permit seeking evidence ..
  40. Multi-Modal Lysosomotropic Death Therapy for Malignant Peripheral Nerve Sheath Tu
    KEVIN AARON karoth@uabedu PROFESSOR & DIRECTOR OF NEUROPATHOLOGY ROTH; Fiscal Year: 2009
    ..provided by applicant): Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, rapidly fatal neoplasms for which new therapeutic approaches are desperately needed...
  41. SSDP2 Gene Pathway in Myeloid Neoplasms
    Lalitha Nagarajan; Fiscal Year: 2006
    ..Thus, the incidence of secondary myeloid neoplasms is likely to increase as we cure other forms of cancer and 50% of secondary myeloid malignancies harbor ..
  42. INTERACTIONS OF ENVIRONMENTAL TOXICANTS WITH LEUKOCYTES
    Michael A Trush; Fiscal Year: 2002
    ..either the production or function of these cells could result in suppressed host defenses against infection and neoplasms. A likely site at which such alterations could occur is in the bone marrow...
  43. IMMUNITY AND INFECTION
    James B Kaper; Fiscal Year: 2007
    ..the leading cause of death worldwide and rank third in the United States behind only heart disease and malignant neoplasms. In addition, recent bioterrorism events both here and abroad, have highlighted our need for researchers trained ..
  44. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    MARIA S soengas@umichedu ASSISTANT PROFESSOR SOENGAS; Fiscal Year: 2009
    ..Nearly all individuals of fair skin bear multiple benign melanocytic neoplasms (nevi) expressing pro- oncogenic mutations in the MAPK pathway, usually in the BRAF or NRAS genes...
  45. Folate, Smoking, Race and Cervical Cancer Risk
    CAPRIMARA FILLMORE; Fiscal Year: 2004
    ..Women with cancer or cervical intraepithelial neoplasms 2 or 3 (CIN 2 or 3) on biopsies will be classified as "high risk"...
  46. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    Maria S Soengas; Fiscal Year: 2008
    ..Nearly all individuals of fair skin bear multiple benign melanocytic neoplasms (nevi) expressing pro- oncogenic mutations in the MAPK pathway, usually in the BRAF or NRAS genes...
  47. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    Maria S Soengas; Fiscal Year: 2008
    ..Nearly all individuals of fair skin bear multiple benign melanocytic neoplasms (nevi) expressing pro- oncogenic mutations in the MAPK pathway, usually in the BRAF or NRAS genes...
  48. Genetically Engineered Mice as Models to Study Receptor
    Glenn Merlino; Fiscal Year: 2006
    ..The childhood malignancy RMS, accounting for up to 10% of all pediatric neoplasms and for more than 50% of pediatric soft tissue sarcomas, is believed to arise from imbalances in skeletal muscle ..
  49. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur S Tischler; Fiscal Year: 2003
    ..Pheochromocytomas are developmentally related to neuroblastomas, which are common adrenal medullary neoplasms, and pheochromocytoma cells can undergo neuronal differentiation...
  50. The role of Ndy1 in epigenetic gene silencing and stem cell biology
    PHILIP N ptsichlis@tuftsmedicalcenterorg PROFESSOR/DIRECTOR TSICHLIS; Fiscal Year: 2009
    ..Our studies have linked Ndy1 to the induction of retrovirus-induced rodent hematopoietic neoplasms. Moreover, examination of its expression in existing databases has shown that Ndy1 is overexpressed in a variety ..
  51. Development and Validation of a FISH-Based Renal Cancer Detection Assay
    Jane Houldsworth; Fiscal Year: 2008
    ..FRCD) kit that is based not on cell morphology, but on the inherent differential genetics of renal cortical neoplasms, for commercial distribution by Cancer Genetics, Inc...
  52. Role of L-3-phosphoserine phosphatase in epidermal growth and survival
    David M Owens; Fiscal Year: 2008
    ..is featured in neurological disorders, Williams-Beuren syndrome, skin ichthyosis and a variety of epithelial neoplasms. However, the significance of altered L3PSP activity on the initiation and course of these diseases is still not ..
  53. Role of L-3 phosphoserine phosphatase in epidermal apoptosis and carcinogenesis
    Michael A Bachelor; Fiscal Year: 2008
    ..is featured in neurological disorders, Williams-Beuren syndrome, skin ichthyosis and a variety of epithelial neoplasms. However, the significance of altered L3PSP activity on the initiation and course of these diseases is still not ..
  54. STAT1 Activation and HPP1 Tumor Suppression
    DAVID shibatd@moffittusfedu SHIBATA; Fiscal Year: 2009
    ..recently identified gene that was initially discovered by virtue of its significant downregulation in colorectal neoplasms derived from patients with Hyperplastic Polyposis...
  55. IRS-1 - JC T-antigen Interaction in Cerebellar Tumors
    Krzysztof Reiss; Fiscal Year: 2006
    Medulloblastomas represent about 25 percent of all pediatric intracranial neoplasms. These highly malignant tumors arise from the cerebellum and affect mainly children between ages five and fifteen...
  56. Translational effects of small molecule cell cycle modul
    Adrian Senderowicz; Fiscal Year: 2004
    ..Molecular and biochemical effects of small molecules cell cycle modulators in patients with advanced neoplasms Searching for available tissues (accessible by non-invasive means), we hypothesized that oral keratinocytes ..
  57. Microarray analysis of thyroid neoplasm
    Martha A Zeiger; Fiscal Year: 2004
    ..Because the surgical management for benign and malignant thyroid neoplasms differ, patients with suspicious FNAs may be treated in a less than ideal fashion surgically...
  58. Ranibizumab (rhuFAB V2) for Advanced Ocular Disease of V
    Emily Y Chew; Fiscal Year: 2005
    ..Hippel-Lindau Syndrome (VHL) is an autosomal dominant heritable disorder in which multiple benign and malignant neoplasms and cysts of specific histopathologies develop in the kidney, adrenal gland, pancreas, brain, spinal cord, eye, ..
  59. Anti-VEGF Pegylated Aptamer for Advanced Ocular Disease
    Emily Y Chew; Fiscal Year: 2005
    ..Hippel-Lindau Syndrome (VHL) is an autosomal dominant heritable disorder in which multiple benign and malignant neoplasms and cysts of specific histopathologies develop in the kidney, adrenal gland, pancreas, brain, spinal cord, eye, ..
  60. In Vivo Detection of Flat Colorectal Neoplasms with CT Colonography
    JANNE jnappi@partnersorg NAPPI; Fiscal Year: 2009
    ..Most colorectal cancers develop from sessile or pedunculated polypoid neoplasms. Early removal of such neoplasms has been observed to reduce the occurrence of colorectal carcinoma...
  61. MOLECULAR PATHOGENESIS OF HYPERPARATHYROIDISM
    Andrew Arnold; Fiscal Year: 2008
    ..mechanisms might be especially important in parathyroid tumors, possibly explaining why these cyclin D1-driven neoplasms are almost always benign in marked contrast with the malignant features of other cyclin D1-induced tumors, and ..
  62. Functions of WRN in Response to DNA Double-Strand Breaks
    DAVID J davidchen@utsouthwesternedu PROFESSOR AND DIRECTOR CHEN; Fiscal Year: 2009
    ..WS patients also experience an increased risk of rare non-epithelial cancers, especially mesenchymal neoplasms such as sarcomas...

Publications62

  1. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives
    Bharat B Aggarwal
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cell Cycle 4:1201-15
    ..Numerous studies have indicated that I3C also has a strong hepatoprotective activity against various carcinogens. Initial clinical trials in women have shown that I3C is a promising agent against breast and cervical cancers...
  2. Cannabinoid receptor systems: therapeutic targets for tumour intervention
    Sarah Jones
    Molecular Pharmacology Group, Biomedical Sciences Division, School of Applied Sciences, University of Wolverhampton, Wulfruna Street, WV1 1SB, UK
    Expert Opin Ther Targets 7:749-58
    ..Thus, this review also summarises the demonstrated antitumour actions of cannabinoids and indicates possible avenues for the future development of cannabinoids as antitumour agents...
  3. Therapeutic potential of target of rapamycin inhibitors
    John B Easton
    St Jude Childrens Research Hospital, Department of Molecular Pharmacology, 332 N Lauderdale Street, Memphis, TN 38105 2794, USA
    Expert Opin Ther Targets 8:551-64
    ....
  4. Proteasome inhibition: a new approach for the treatment of malignancies
    Jean Philippe Spano
    Département d oncologie médicale, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France
    Bull Cancer 92:E61-6, 945-52
    ..This review provides a summary of the rationale for using proteasome inhibitors and an update on available and ongoing clinical studies involving human malignancies...
  5. Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  6. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo
    Fang Tian
    Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Science, Chinese Academy of Sciences, PR China
    Cancer Biol Ther 4:874-82
    ....
  7. Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative
    Eui-Yeun Yi
    Department of Molecular Biology, Pusan National University, Pusan 609-735, Korea
    Int J Oncol 25:365-72
    ..Taken together, these results suggest that SJ-8002 may be a candidate for strong anti-cancer agent with the ability to inhibit the angiogenesis of endothelial cells and to induce the apoptosis of tumor cells...
  8. Modulation of tumor induced angiogenesis in Ehrlich ascites tumor
    S Ghosh
    Dept of Metabolic Regulation, Chittaranjan National Cancer Institute, Kolkata, India
    J Exp Clin Cancer Res 23:681-90
    ..Treatment with enzyme reduced serum VEGF levels of the tumor induced animals. In vitro VEGF production by EAC cells was reduced in a concentration dependent manner in presence of glutamine analogue...
  9. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics
    Lyubomir T Vassilev
    Roche Research Center, Hoffman La Roche Inc, Nutley, New Jersey 07110, USA
    Cell Cycle 3:419-21
    ..Their potent activity against osteosarcoma xenografts suggests that MDM2 antagonists may have clinical utility in the treatment of tumors with wild-type p53...
  10. Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis
    Lynn Bonham
    Cell Therapeutics, Inc, 201 Elliott Avenue West, Suite 400, Seattle, WA 98119, USA
    Expert Opin Ther Targets 7:643-61
    ..These discoveries indicate that LPAAT-beta represents a potential novel cancer therapy target...
  11. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
    S S Dharap
    Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
    Proc Natl Acad Sci U S A 102:12962-7
    ....
  12. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists
    Christian Grommes
    Department of Neurosciences, Alzheimer Research Laboratory, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
    Lancet Oncol 5:419-29
    ..Here, we review PPAR gamma-induced antineoplastic signalling pathways, and summarise the antineoplastic effects of PPAR gamma agonists in different cancer cell lines, animal models, and clinical trials...
  13. STAT proteins as novel targets for cancer drug discovery
    James Turkson
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, SRB 22214, Tampa, FL 33612, USA
    Expert Opin Ther Targets 8:409-22
    ..An update on the efforts to develop novel Stat3 inhibitors for therapeutic application will also be provided...
  14. Overview of tumor cell chemoresistance mechanisms
    Laura Gatti
    Istituto Nazionale Tumori, Milan, Italy
    Methods Mol Med 111:127-48
    ..This chapter presents an overview of the drug resistance mechanisms...
  15. TRAIL and anti-tumor responses
    Mahaveer Swaroop Bhojani
    Center for Molecular Imaging, Departments of Radiology, University of Michigan; Ann Arbor, Michigan 48109-0648, USA
    Cancer Biol Ther 2:S71-8
    ..Only time will tell whether the search for the Holy Grail for treatment of cancer will end with TRAIL?..
  16. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs
    Michela Giuliano
    Dipartimento di Biologia Cellulare e dello Sviluppo, Sezione di Biochimica, Policlinico, Università di Palermo, Italy
    Ital J Biochem 52:112-21
    ..PS-341 represent the first of this promising class of agents that could have application in cancer therapy and it is the only that has progressed to clinical trials...
  17. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth
    Stella Pelengaris
    Molecular Medicine, Biomedical Research Institute, University of Warwick, Coventry, CV4 7AL, UK
    Expert Opin Ther Targets 7:623-42
    ..Although still in its infancy, encouraging results have been reported using antisense oligodeoxynucleotide-based methods, as well as other approaches to interfere with MYC expression both in vitro and in vivo...
  18. Embryonic apoptosis-inducing proteins exhibited anticancer activity in vitro and in vivo
    C L Yu
    Ambryx Biotechnology Inc, Oak Park, CA 91377, USA
    Anticancer Res 21:1839-56
    ..This new concept may constitute a new approach for cancer therapy, which we tentatively designated as "Retro-differentiational Apoptosis Cancer Therapy", (R-ACT)...
  19. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1
    Makoto Hiromura
    Division of Cancer Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    J Biol Chem 279:53407-18
    ..This observation will facilitate the design of specific inhibitors for Akt, a core intracellular survival factor underlying various human neoplastic diseases...
  20. Novel anticancer agents in clinical development
    Alex A Adjei
    Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
    Cancer Biol Ther 2:S5-15
    ..This review will highlight promising rationally designed, target-based agents in clinical development, as well as the unique challenges involved in their successful development...
  21. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
    Jianzhong Huang
    Division of Pediatric Surgery, Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 100:7785-90
    ..Potent blockade of VEGF may provide a new therapeutic option for patients with bulky, metastatic cancers...
  22. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling
    Pierangela Totta
    Department of Biology, University Roma Tre, Viale G Marconi, 446, I 00146 Rome, Italy
    IUBMB Life 56:491-9
    ..These findings indicate new steps in the mechanism underlying ER-dependent anti-proliferative effects of Nar suggesting new potential chemopreventive actions of flavonoids on cancer growth...
  23. Targeted drug delivery in cancer therapy
    Jaspreet K Vasir
    Department of Pharmaceutical Sciences, College of Pharmacy, 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA
    Technol Cancer Res Treat 4:363-74
    ..This article reviews the possibilities and challenges for targeted drug delivery in cancer therapy...
  24. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines
    Marina Maggiora
    Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Torino, Italy
    Int J Cancer 112:909-19
    ..In conclusion, CLA may be regarded as a component of the diet that exerts antineoplastic activity and its effect may be antiproliferative or pro-apoptotic...
  25. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1
    Eun-Jin Yeo
    Department of Pharmacology, BK21 Human Life Sciences, Seoul National University College of Medicine, Seoul, Korea
    J Natl Cancer Inst 95:516-25
    ..YC-1 has the potential to become the first antiangiogenic anticancer agent to target HIF-1 alpha...
  26. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
    Hak Choy
    Vanderbilt Ingram Cancer Center, Nashville, TN, USA
    J Natl Cancer Inst 95:1440-52
    ..Results of current early-phase studies of non-small-cell lung, esophageal, cervical, and brain cancers will determine whether therapies that combine COX-2 inhibitors and radiation will enter randomized clinical trials...
  27. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy
    Joachim Drevs
    Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany
    Anticancer Res 24:1759-63
    ..In summary, all chemotherapeutic agents were more active against endothelial cells in comparison to tumor cells. The hypothesis of an antiangiogenic active metronomic therapy could be confirmed in vivo by the use of adriamycin in RENCA...
  28. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin
    Jun Fang
    Department of Microbiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Int J Cancer 109:1-8
    ..Further study of the effect of PEG-ZnPP plus conventional anticancer drugs that generate ROS, such as cisplatin, camptothecin, doxorubicin, mitomycin C and etoposide, is warranted...
  29. A glance at adenosine receptors: novel target for antitumor therapy
    Stefania Merighi
    Pharmacology Unit, Department of Clinical and Experimental Medicine, Via Fossato di Mortara 17-19, 44100, Ferrara, Italy
    Pharmacol Ther 100:31-48
    ..We venture to suggest that the clarification of the role of adenosine and its receptors in cancer development may hold great promise for the treatment of chemotherapy in patients affected by malignancies...
  30. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation
    Jung-Hyun Park
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Clin Cancer Res 10:5271-81
    ..Therefore, based on isotype specificity and antitumor activity, SK-7041 and SK-7068 HDAC inhibitors are expected to be promising anticancer therapeutic agents and need additional clinical development...
  31. Morphologic instability and cancer invasion
    Vittorio Cristini
    Department of Biomedical Engineering, University of California, Irvine, California 92697 2715, USA
    Clin Cancer Res 11:6772-9
    ....
  32. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents
    Henriette Gourdeau
    Shire BioChem, Inc, Laval, Quebec, Canada
    Mol Cancer Ther 3:1375-84
    ..Our results identify MX-116407 as the lead candidate and strongly support its continued development as a novel anticancer agent for human use...
  33. Potential role of the antiproliferative cytokine beta-galactoside binding protein in cancer therapy
    Livio Mallucci
    King s College London, Cell Signalling and Growth Laboratory, Division of Pharmaceutical Sciences, School of Health and Life Sciences, Franklin Wilkins Building, London, UK
    Curr Opin Investig Drugs 6:1228-33
    ....
  34. 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity
    Tarik Z Belhocine
    Department of Nuclear Medicine, Jules Bordet Cancer Institute, Brussels, Belgium
    Methods Mol Med 111:363-80
    ..Alternative methods for Annexin A5 labeling and imaging may improve the detection of drug-induced apoptosis to monitor chemosensitivity...
  35. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine
    H Maeda
    Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies, Kyoto 606-8501, Japan
    Cell Death Differ 11:737-46
    ..Furthermore, because the effective doses of both compounds are within clinically achievable range, this report will lead to immediate benefit for the development of a new cancer therapy...
  36. Exploitation of the HIF axis for cancer therapy
    Daniel Escuin
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Cancer Biol Ther 3:608-11
    ..We will overview inhibitors of HIF-1alpha and will discuss their potential use for cancer therapy...
  37. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo
    Ching-Chuan Kuo
    Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan, ROC
    Cancer Res 64:4621-8
    ..v. doses of 50 mg/kg in nude mice. These findings indicate BPR0L075 is a promising anticancer compound with antimitotic activity that has potential for management of various malignancies, particularly for patients with drug resistance...
  38. Increased cytotoxicity of 2',2'-difluoro-2'-deoxycytidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine
    A C Verschuur
    Laboratory of Genetic Metabolic Diseases, Division of Clinical Chemistry, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Nucleosides Nucleotides Nucleic Acids 23:1517-21
    ..We conclude that CPEC enhances the incorporation of dFdCTP into DNA and thus increases the cytotoxicity of gemcitabine in lymphocytic and myeloid leukemic cell-lines...
  39. Cisplatin and platinum drugs at the molecular level. (Review)
    Teni Boulikas
    Regulon, Inc, Mountain View, CA 94043, USA
    Oncol Rep 10:1663-82
    ..Particularly important are combinations of platinum drug treatments with other drugs, radiation and the emerging gene therapy regimens...
  40. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha
    Sarah Welsh
    Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
    Mol Cancer Ther 3:233-44
    ....
  41. An inhibitor of Bcl-2 family proteins induces regression of solid tumours
    Tilman Oltersdorf
    Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, California 92121, USA
    Nature 435:677-81
    ....
  42. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)
    Anne Marie Byrne
    Royal College of Surgeons in Ireland, Department of Surgery, Education and Research Centre, Beaumont Hospital, Dublin
    J Cell Mol Med 9:777-94
    ..Finally, we discuss the therapeutic implications of targeting angiogenesis and VEGF receptors, particularly in cancer therapy...
  43. Taurolidine--a new drug with anti-tumor and anti-angiogenic effects
    Christoph A Jacobi
    Department of General, Visceral, Vascular and Thoracic Surgery, Medical Faculty Charité, Humboldt University, Berlin, Germany
    Anticancer Drugs 16:917-21
    ..Prospective clinical studies are currently investigating the efficacy of TRD on local and metastatic tumor growth in different malignancies...
  44. [Development of the protein microarray technique and usefulness in individualized molecular tumor therapy]]
    Virginia Espina
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
    Onkologie 28:40-2
  45. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo
    Stephanie L Matheson
    Cancer Drug Research Laboratory, Department of Medicine, McGill University Health Center/Royal Victoria Hospital, 687 Pine Ave. West, M7.19, Montreal, QC H3A 1A1, Canada
    J Pharmacol Exp Ther 311:1163-70
    ..These results suggest that the binary targeting properties of SMA41 are associated with a binary cascade of events in the cells that seem to culminate into significant growth inhibition in vitro and in vivo...
  46. Cancer research. Obstacle for promising cancer therapy
    Jean Marx
    Science 295:1444
  47. Cyanidin 3-glucoside and peonidin 3-glucoside inhibit tumor cell growth and induce apoptosis in vitro and suppress tumor growth in vivo
    Pei-Ni Chen
    Institute of Biochemistry, Chung Shan Medical University, Taichung, Taiwan
    Nutr Cancer 53:232-43
    ..Furthermore, anthocyanins from O. sativa L. indica were evidenced by their inhibition on the growth of Lewis lung carcinoma cells in vivo...
  48. Grifolin, a potential antitumor natural product from the mushroom Albatrellus confluens, inhibits tumor cell growth by inducing apoptosis in vitro
    Mao Ye
    Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
    FEBS Lett 579:3437-43
    ....
  49. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy
    Wim K Bleeker
    Genmab BV, Utrecht, The Netherlands
    J Immunol 173:4699-707
    ..Taken together, our findings indicate that ADCC represents an important effector mechanism of this Ab, which is effective at relatively low dose...
  50. Activity of epothilones
    Ada Kolman
    Department of Molecular Biology and Functional Genomics, Stockholm University, 106 91 Stockholm
    Curr Opin Investig Drugs 6:616-22
    ..Several epothilones are undergoing clinical evaluation and are promising candidates for advanced cancer therapy...
  51. Reprogramming RelA
    Kirsteen J Campbell
    School of Life Sciences, Division of Gene Regulation and Expression, MSI/WTB Complex, University of Dundee, Dundee, Scotland
    Cell Cycle 3:869-72
    ..The identification of these pathways not only allows a reinterpretation of NF-kappaB function in normal cells and during tumorigenesis but could also have implications for both traditional and NF-kappaB based cancer therapy...
  52. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
    Yan Wang
    Department of Oncology, Schering Plough Research Institute, 2015 Galloping Hill Road, K15 4600, Kenilworth, NJ 07033, USA
    Mol Cancer Ther 4:1214-21
    ..In vivo, 19D12 inhibits the tumor growth of a very aggressive human ovarian tumor xenograft model A2780. These data support the development of this anti-IGF-IR monoclonal antibody as a promising anticancer agent...
  53. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
    Haidong Dong
    Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA
    Nat Med 8:793-800
    ..These findings have implications for the design of T cell-based cancer immunotherapy...
  54. Apoptosis in cancer--implications for therapy
    Henning Schulze-Bergkamen
    Tumor Immunology Program, German Cancer Research Center, Heidelberg, Germany
    Semin Oncol 31:90-119
    ..In this review we address the role of apoptosis signaling in tumorigenesis and drug resistance of tumor cells and discuss therapeutic approaches interfering with apoptosis pathways...
  55. In vivo antitumor activity of Sindbis viral vectors
    Jen-Chieh Tseng
    NYU Cancer Institute, Rita J. and Stanley H. Kaplan Comprehensive Cancer Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    J Natl Cancer Inst 94:1790-802
    ..B-17-SCID beige mice treated with SinRep/LacZ. CONCLUSION: Sindbis viral vectors efficiently targeted tumors in vivo, were apparently delivered through the circulation, and were more effective in the presence of NK cells...
  56. Cardiotonic steroids: potential endogenous sodium pump ligands with diverse function
    Renata I Dmitrieva
    Institute of Molecular Medicine, University of Texas, Houston, Texas 77030, USA
    Exp Biol Med (Maywood) 227:561-9
    ..This signaling may influence cell survival, growth, and differentiation. Recent insight into the biology of pump regulation by CS is reviewed...
  57. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone
    Lyudmila Burdelya
    Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Mol Cancer Ther 1:893-9
    ..These results suggest that JAK/STAT inhibitors deserve further investigation for use with IL-12 therapy in treating human cancers with elevated JAK/STAT activity...
  58. Gene therapy strategies to improve the effectiveness of cancer radiotherapy
    Svend O Freytag
    Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202 3405, USA
    Expert Opin Biol Ther 4:1757-70
    ..Here, the results of the clinical trials conducted so far will be reviewed, followed by a description of new approaches under development at present...
  59. Clinical development of decitabine as a prototype for an epigenetic drug program
    Craig S Rosenfeld
    Semin Oncol 32:465-72
    ..Optimized decitabine doses and combinations with other epigenetic therapies that can be used at minimally toxic doses provide potentially safer therapeutic options and introduce novel combination therapies...
  60. Bcl-2: prevention of apoptosis as a mechanism of drug resistance
    J C Reed
    La Jolla Cancer Research Foundation, Cancer Research Center, California, USA
    Hematol Oncol Clin North Am 9:451-73
    ....